Two Sigma Investments, LP Neu Base Therapeutics, Inc. Transaction History

Two Sigma Investments, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.82 - $1.93 $8,382 - $19,728	-10,222 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.26 - $2.95 $12,879 - $30,154	10,222 New	10,222 $19,000
Q4 2021 Feb 14, 2022	SELL	$2.6 - $4.18 $223,069 - $358,627	-85,796 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$3.27 - $4.76 $324,171 - $471,882	-99,135 Reduced 53.61%	85,796 $310,000
Q2 2021 Aug 16, 2021	BUY	$4.63 - $7.34 $428,770 - $679,735	92,607 Added 100.31%	184,931 $886,000
Q1 2021 May 17, 2021	BUY	$6.92 - $12.36 $638,882 - $1.14 Million	92,324 New	92,324 $682,000
Q3 2020 Nov 16, 2020	SELL	$7.25 - $9.71 $82,860 - $110,975	-11,429 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $76,460 - $131,547	11,429 New	11,429 $100,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.